Business
Britain goes on COVID-19 vaccine spending spree – The Australian Financial Review
The race is heating up among rich nations eager to get hold of stocks of as-yet unproven vaccines.
The US has booked 300 million of AstraZeneca’s first billion doses, and last week nailed a $US1.95 billion ($2.7 billion) deal with Pfizer for 100 million doses, with an option to secure an additional 500 million doses.
And the European Union is in talks with at least half a dozen developers, including Pfizer, Sanofi and Johnson & Johnson, but Reuters has reported this week that haggling continues over the price, payment method and potential liability costs.
Countries have a duty to protec…
-
Business22 hours agoThis ASX 200 mining stock is eyeing the lithium throne
-
Noosa News20 hours agoDriver arrested after life-threatening hit-and-run on outskirts of Ipswich, Queensland
-
Business20 hours agoThe best ASX shares to buy and forget for 10+ years
-
Noosa News22 hours agoBrisbane lawyer Christopher Saines dies unexpectedly after massage while on holiday in Thailand